All In Biotech

Drug Trial Radar · NCT06810544

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

191

Planned (sponsor's estimate)

Start

Mar 24, 2025

Primary completion

Mar 31, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Tango Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Feb 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.

Conditions

  • Non Small Cell Lung Cancer
  • Glioma Glioblastoma Multiforme
  • Glioma, Malignant
  • Solid Tumor
  • Non-Small Cell Adenocarcinoma
  • Lung Cancer
  • Brain Tumor

Interventions

  • TNG456Drug

    A selective PRMT5 inhibitor

  • abemaciclibDrug

    A kinase inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 Maximum Tolerated DoseTime frame: 21 days
  2. Phase 2 Anti-neoplastic Activity Single AgentTime frame: 18 weeks
  3. Phase 2 Anti-neoplastic Activity Combination TreatmentTime frame: 18 weeks

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona · Recruiting

  • University of California, Irvine

    Irvine, California · Recruiting

  • University of California Los Angeles

    Los Angeles, California · Recruiting

  • University of California at San Francisco

    San Francisco, California · Recruiting

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • Northwestern Memorial Hospital

    Chicago, Illinois · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Clinic Cancer Center

    Rochester, Minnesota · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Utah, Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.